Brazil announced on Tuesday the results of the Phase III clinical trial of the Chinese Kexing vaccine, which showed that the new crown vaccine developed by China’s Kexing Biologicals was only 50.38 percent effective. This is almost 30 percentage points lower than the initial results announced last week.
The results were announced Tuesday by the Instituto Butantan in São Paulo, which is responsible for vaccine development and clinical trials in Brazil.
According to the final results of the trial, the new crown vaccine from Coxin Biologics meets the minimum conditions set by the World health Organization for vaccine effectiveness to exceed 50 percent, but it is much less effective than the vaccine developed by Pfizer and German biotechnology, which is 95 percent effective, and the vaccine developed by Modena, which is 94.1 percent effective.
The Butantan Institute announced last week, and reiterated on Tuesday, that the overall effectiveness of the Coxin vaccine is 78%, and that the trial with 12,508 volunteers showed that the effectiveness in stopping severe disease continues to be 100%.
On Friday, the Butantan Institute submitted an application to the Brazilian National Health Surveillance Agency for the marketing of the Coxin vaccine. The application was also filed for a vaccine developed by AstraZeneca and Oxford University.
Brazil has a total of 212 million people and more than 203,000 have died from the new coronavirus and 8 million have been diagnosed.
Recent Comments